The treatment of Multiple Myeloma has undergone significant changes in recent years thanks to advancements in understanding the disease and the increasing availability of new therapeutic agents.
A better understanding of the biology of Multiple Myeloma has made it possible to more accurately identify patients with aggressive disease who require treatment, as well as to stratify the likelihood of response to therapy and long-term survival. New diagnostic approaches, including flow cytometry, radiological, and molecular techniques, now allow the identification of high-risk factors and the measurement of minimal residual disease (MRD) with a sensitivity that was unimaginable just a few years ago.
Advances in therapy have provided clinicians with a vast arsenal of treatment options: the field has shifted from standardized therapy for all patients based on transplant eligibility to the availability of multiple drugcombinations for each line of therapy, requiring increasingly personalized choices. MRD is a new primary endpoint in clinical trials, and in daily clinical practice it will enable targeted personalized therapeutic decisions.
This conference will bring together national and international experts to provide a comprehensive and cross-disciplinary overview of the current state of knowledge on Multiple Myeloma, from its biological foundationsto the latest diagnostic and therapeutic innovations.
Only through a deep understanding by healthcare and research professionals of the changes in the field of Multiple Myeloma will it be possible for patients to fully benefit from the progress achieved so far and from those yet to come.

SCIENTIFIC DIRECTORS